Thousands of calls began to come out, Karelli Zhu single resistance successfully entered the new version of the national health insurance directory

On December 28, 2020, the 2021 National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs was officially published.
Henrui Pharmaceuticals' self-developed PD-1 inhibitor, Kareli Zhudai (Erika ®️), successfully entered the health insurance list for the treatment of advanced lung, liver, esophageal and Hodgkin's lymphoma.
this means that all four of the current major adaptive disorders of Karelli's mono-resistance are covered by health insurance.
same time, another heavy-weight chemotherapy drug injected with yew alcohol (albumin binding type) (Ai Yue ®️) was added to the national health insurance list.
note that in the field of lung, liver and esophageal cancers, PD-1/L1 drugs from no other pharmaceutical company are covered by health insurance, except for Carelli's monoantigen.
next year, Karelli's monotherapy will be the only immunotherapy drug among the three cancers that can be reimbursed for health insurance.
Since its launch in 2019, Karelli Zhudao has been successfully approved for four major adaptive diseases, namely lung cancer, liver cancer, esophageal cancer and lymphoma, and has been recommended by the Chinese Society of Clinical Oncology (CSCO) guidelines for multiple tumors, and has been awarded the international academic stage many times.
this round of health care negotiations to a large number of anti-tumor drugs into the national health insurance directory, highlighting the national and government care for cancer patients, more reflect the role of large countries.
believes that with the successful entry of Karelli-Zhu single resistance into the national health insurance directory, the beneficiaries of immunotherapy will be further expanded, and more cancer patients will benefit.
The only reimbursable PD-1 single-anti-renewal national health insurance directory for people's lung, liver and esophageal cancer shows that in 2021, the four major indications of Carelli's single anti-lung cancer, liver cancer, esophageal cancer and lymphoma will be included in the national health insurance catalogue.
will greatly ease the financial pressure on cancer patients, completely changing the past many cancer patients have good medicine "dare not to use, can not afford" situation.
And from the medical insurance published reimbursable adaptive disorders, Karelli pearl single anti is the only lung cancer, liver cancer, esophageal cancer patients to enjoy the health insurance reimbursement policy PD-1 single resistance, other PD-1 drugs are not available for reimbursement of the three major cancers.
epidemiological data show that lung, liver and esophageal cancer accounted for the first, third and fifth place in the number of new cancer patients in China.
carelli's single-up health insurance will allow immunotherapy to better reach millions of patient groups, so that ordinary people enjoy the dividends of original research innovation.
Evidence-based full, safe, reliable and strong efficacy by the international academic community highly recognized for immunotherapy drugs, access to health insurance is not an end in itself, only on the basis of excellent efficacy to reduce prices, can be said to be a real benefit to people's livelihood.
is exactly what The Carelli Pearl single resistance is all about.
since its launch in August 2019, Karelli-Pearl has been approved for advanced adaptation to Hodgkin's lymphoma, liver cancer, non-squamous non-small lung cancer, and esophageal squamous cancer.
clinical study data show that Karelli-Pearl monoantigen has shown strong efficacy and excellent safety in all cancer species.
In the field of lung cancer, led by Professor Zhou Caizhu of Shanghai Lung Hospital affiliated with Tongji University, the results of the world's first phase III study (CameL study) of non-squamous non-small cell lung cancer (NSCLC) first-line immunogenic combined chemotherapy for group Chinese groups showed that the treatment of carelli-zhu single anti-combination chemotherapy led by gene-negative non-small cell lung cancer achieved excellent results of ORR 60.5% and 11.3 months of non-progressive survival.
As recently as December 19th, CameL's research was published in the Lancet Respiratory Medicine, the world's top academic journal, and data showed that the updated mOS lasted 27.9 months, creating a new high for the total survival of advanced lung cancer treatment and creating new hope for lung cancer patients.
In the field of liver cancer, a multi-center, Phase II clinical study of china's advanced hepatocellular carcinoma, led by Professor Qin Shuxuan of Jinling Hospital in Nanjing and Professor Ren Zhenggang of Zhongshan Hospital affiliated with Fudan University, showed that mOS reached 13.8 months and patients orR reached 14.7%, an increase of 110% compared to the standard second-line targeted treatment plan ORR.
the study, published online February 26 in The Lancet Oncology, became the first immunotherapy study of liver cancer in China to reach the top of the Lancet.
the first and only approved hepatic cancer adaptation PD-1 monoantigen with this research.
In the field of esophageal cancer, the results of the study on advanced/metastatic esophageal squamous cancer (ESCORT study) led by Professor Huang Mirror of the Oncology Hospital of the Chinese Academy of Medical Sciences and Professor Xu Jianming of the Fifth Medical Center of the PLA General Hospital showed that the patients in the Carelli-Pearl single anti-treatment group had ORR of 20.2% and mOS of 8.3 months, and had benefited from the whole population.
this study broke through the survival bottleneck of esophageal squamous cancer in the past few decades, which is a landmark study in the field of esophageal cancer.
with outstanding data and breakthroughs, ESCORT research is also on the board of The Lancet Oncology.
in the field of lymphoma, the CR rate of patients with carelli-pearl monoantigen therapy for recurrence/refractic classic Hodgkin's lymphoma was 71%, and 100% of patients who continued to respond for 6 months.
the study was published in the American Journal of Clinical Oncology with excellent data.
Karelliju monoantigen not only received high-level evidence-based evidence support, but also performed well in terms of safety, and its adverse reactions were mostly level one, two, three and above, the rate of adverse reactions was low, and the patient's tolerance was good.
in the clinical guidelines for lung cancer, liver cancer, esophageal cancer and lymphoma published by CSCO this year, Kareliju monoantigen was recommended by the guidelines, becoming the only immunotherapy drug in China to achieve this achievement.
original research innovation, ingenuity to open a new era of China's immunotherapy Karelli Zhu single resistance after 10 years of research and development, condensing the wisdom of Chinese medical researchers.
the breakthrough in clinical trials is inextricable to its excellent drug design.
data show that the EC50 value of Karelli pearl monoantigen is 0.38nM, IC50 value is 0.7nM, its subject affinity is about 4 times that of other similar drugs, so it is also known by experts as "strong antibody".
this reason, its clinical efficiency in lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and other clinical efficiency, total survival is also generally higher than other immunochemical checkpoint inhibitors.
it is known that EC50 refers to half of the effect concentration, IC50 refers to half of the inhibition concentration, the lower the two indicators, indicating that PD-1 monoantigen and T cell affinity, the stronger the drug effect.
data show that 22 days after a single drug, the market share of carelli's monoantigen is still as high as 95%.
, on the other hand, a meta-analysis published in JAMA Oncology, a top journal of the Oncology Society, shows that PD-1 inhibitors have an advantage over PD-L1 inhibitors.
the study collected data from 19 randomized, controlled clinical trials involving 11,379 patients with stomach cancer, non-small cell lung cancer, renal cell carcinoma, urethra skin cancer, and had a high level of evidence.
In addition to the four adaptive disorders included in the scope of medical insurance reimbursement, Karelli Zhusan in recent years in the field of nasopharyngeal cancer, cervical cancer, lung squamous cancer and other diseases have achieved significant therapeutic results, this reduction in health insurance prices for these patients is also a huge positive.
the spread of new drugs requires finding the right balance between drug prices and technology, and access to health insurance is the best opportunity to find that balance.
From 2018 the first immunotherapy drug listed in China, the past two years, although the immunotherapy has repeatedly seen new progress, but from the real widespread popularity of a certain distance, and with the Carelli Pearl single anti-carrying four major adaptive disorders into the national health insurance, China's new era of immunotherapy has been "bullet loaded", only waiting to pull the "New Year's trigger."
More importantly, with Karelli-Zhu single anti-drug and other immunotherapy drugs into health insurance as a sign, China's clinical tumor treatment further narrowed the time difference with developed countries, which is the result of several generations of Chinese researchers to work together, is the result of the courage of new drug policy makers reform, is the result of long-term support from all walks of life, and ultimately let China's patient survival opportunities stand on the same starting line as other countries.
't just fight for the night, not to lose the chinese.
Standing at the point of handover between 2020 and 2021, we look forward to the future of China's new drug research and development can bring us more surprises, to meet more unsoponsed clinical needs, so that more good medicine to save people into thousands of households, to bring patients more life hope and dignity of life.
。